Drug Profile
C4X 3256
Alternative Names: 14C-IDV184001; 14C-IDV184001AN; C4X-3256; INDV-2000Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator C4X Discovery
- Developer C4X Discovery; Indivior
- Class Drug withdrawal therapies; Small molecules
- Mechanism of Action Orexin receptor type 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Substance-related disorders
- No development reported Opioid-related disorders
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Opioid-related-disorders in USA (PO, Capsule)
- 03 Aug 2023 Indivior plans a phase I INDV-2000-105 trial for Opioid-related disorders (In Volunteers) in August 2023 (PO, Suspension) (NCT05974046)
- 01 Aug 2023 C4X Discovery terminates its licence for C4X 3256